Blue Cross & Blue Shield of Florida, Inc. v. Jazz Pharmaceuticals, Inc.
- Docket:
- 3:23-cv-01453
- Court:
- N.D. Fla.
- Filed:
- 2023-12-11
Xyrem antitrust action; US 7,765,107 is listed among the patents at issue in the narrative.
Plaintiff
2 cases as plaintiff.
Blue Cross & Blue Shield of Florida, Inc. (commonly known as Florida Blue) is a Jacksonville, Florida–headquartered health insurer at 4800 Deerwood Campus Parkway. Its predecessor Blue Cross plan was founded in 1944; the Blue Cross and Blue Shield plans merged in 1980 under the current legal name, which was rebranded Florida Blue in 2012. It is a not-for-profit, policyholder-owned mutual and an independent licensee of the Blue Cross Blue Shield Association. Since a 2013–2014 reorganization it has been a wholly owned subsidiary of GuideWell Mutual Holding Corporation, also based in Jacksonville.
Florida Blue is Florida's largest health insurer, selling individual/family, employer group, Medicare Advantage and Part D, and Medicaid products, and administering self-funded (ASO) plans. Parent GuideWell is a diversified health-solutions enterprise (~$32B revenue and roughly 18,000 employees per 2024–2025 company statements, citing 38.5M people served across 50 states) whose holdings include Puerto Rico's Triple-S, GuideWell Health's Sanitas primary/urgent-care centers, and WebTPA (third-party benefits administration).
Litigation posture: Operating company, not an NPE. The structured data shows 2 plaintiff cases and 0 defendant cases — consistent with an insurer affirmatively pursuing recovery claims rather than a shell licensor asserting an acquired patent portfolio. Both tracked matters were filed on 2023-12-11 in the M.D. Fla. and N.D. Fla.; neither venue is an NPE-favored forum.
Notable cases: Both are Blue Cross & Blue Shield of Florida, Inc. v. Jazz Pharmaceuticals, Inc. The M.D. Fla. complaint (3:23-cv-01453), filed with affiliate Health Options, alleges Jazz and generic manufacturers (Hikma, Amneal, Lupin, Par) used reverse-payment patent settlements and related conduct to delay generic Xyrem (sodium oxybate), causing supracompetitive prices — a claim under FTC v. Actavis. It was transferred to the In re Xyrem (Sodium Oxybate) Antitrust Litigation MDL (No. 20-md-02966, N.D. Cal.) in January 2024. These are patent-related antitrust claims; the company asserted no patents.
Xyrem antitrust action; US 7,765,107 is listed among the patents at issue in the narrative.
Antitrust case citing the '275 patent; Jazz defendants were dismissed with plaintiffs' consent by order around Oct. 1, 2025.